Edwards SVP withholds 176 shares for taxes

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026.

Accepted by SEC EDGAR 02/23/2026 - 05:08 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported a Form 4 showing a tax-withholding disposition of 176 shares of common stock on February 22, 2026. The shares were disposed of at a reported price of $79.78 per share, and he now directly holds about 9,089.4805 shares.

Insider Trade Summary

Exercise Price or Tax Liability: 176 shares

Exercise Price or Tax Liability 1 txn

Insider Dahl Andrew M.

Role SVP, Corporate Controller

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	176	$79.78	$14K

Holdings After Transaction: Common Stock — 9,089.4805 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edwards Lifesciences (EW) report for Andrew M. Dahl?

Edwards Lifesciences reported that SVP and corporate controller Andrew M. Dahl disposed of 176 shares of common stock. The Form 4 describes this as a tax-withholding disposition rather than an open-market sale, reflecting shares used to cover tax obligations on equity compensation.

Was the Edwards Lifesciences (EW) insider transaction a typical sale of shares?

No, the transaction was coded “F,” indicating a tax-withholding disposition, not an open-market sale. Shares were delivered to satisfy exercise price or tax liabilities related to equity compensation, a routine administrative transaction commonly seen in executive stock awards.

How many Edwards Lifesciences (EW) shares did Andrew M. Dahl dispose of?

Andrew M. Dahl disposed of 176 shares of Edwards Lifesciences common stock. The transaction was recorded at a price of $79.78 per share and classified as a tax-withholding disposition associated with equity compensation, rather than a discretionary sale into the market.

How many Edwards Lifesciences (EW) shares does Andrew M. Dahl hold after this filing?

After the reported transaction, Andrew M. Dahl directly holds 9,089.4805 shares of Edwards Lifesciences common stock. This figure reflects his remaining direct ownership following the 176-share tax-withholding disposition reported in the Form 4 filing with the SEC.

What does transaction code “F” mean in the Edwards Lifesciences (EW) Form 4?

Transaction code “F” on the Form 4 means shares were used to pay an exercise price or tax liability. In this case, it signals a tax-withholding disposition, where 176 shares were withheld or delivered to satisfy tax obligations tied to equity-based compensation.

Is the Edwards Lifesciences (EW) insider trade classified as a buy or a sell?

The transaction is classified as a disposition related to tax withholding, not a typical buy or sell. The filing describes it as a payment of exercise price or tax liability by delivering securities, which is an administrative step tied to executive stock compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahl Andrew M.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corporate Controller

3. Date of Earliest Transaction (Month/Day/Year)
02/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/22/2026		F		176	D	$79.78	9,089.4805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

	Linda J. Park, Attorney-in-Fact	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.